Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 7Observational 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Blood Specimen Collection 32Surveys and Questionnaires 24Radiotherapy 12Gene Expression Profiling 12Drug Therapy 12Surgical Procedures, Operative 11Bronchoscopy 10Magnetic Resonance Spectroscopy 9Immunotherapy 9Immunohistochemistry 9Tomography, X-Ray Computed 8Specimen Handling 8Observation 8Amplified Fragment Length Polymorphism Analysis 8Polymerase Chain Reaction 7pembrolizumab 6Psychiatric Rehabilitation 6Interviews as Topic 6Carboplatin 6Thoracic Surgery, Video-Assisted 5Reverse Transcriptase Polymerase Chain Reaction 5Microarray Analysis 5Liquid Biopsy 5Chemoradiotherapy 5Bevacizumab 5durvalumab 4Therapeutics 4Paclitaxel 4Nivolumab 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Lung Neoplasms × capmatinib × Clear all
NCT05703516 2025-01-14

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Novartis

Recruiting
250 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03192501 2024-06-25

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Second Affiliated Hospital of Guangzhou Medical University

Recruiting
250 enrolled
Thoracic

Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡